135 related articles for article (PubMed ID: 26320514)
41. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
42. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Fujimoto N
Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
[TBL] [Abstract][Full Text] [Related]
43. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
Eur Urol; 2017 May; 71(5):838-840. PubMed ID: 28189430
[No Abstract] [Full Text] [Related]
44. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Ohlmann CH; Goebell PJ; Grimm MO; Klier J; König F; Machtens S; Schostak M; Schrader AJ; Albers P
Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
[TBL] [Abstract][Full Text] [Related]
45. Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018.
Marandino L; De Luca E; Zichi C; Lombardi P; Reale ML; Pignataro D; Di Stefano RF; Ghisoni E; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Buttigliero C; Tucci M; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Clin Genitourin Cancer; 2019 Oct; 17(5):332-347.e2. PubMed ID: 31416754
[TBL] [Abstract][Full Text] [Related]
46. Treatment for castration-resistant prostate cancer and drug interaction risk in polymedicated patients.
Juárez Soto A
Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):641-643. PubMed ID: 32829931
[No Abstract] [Full Text] [Related]
47. Are we doing the right phase III trials?
Burton A
Lancet Oncol; 2007 Mar; 8(3):193. PubMed ID: 17348107
[No Abstract] [Full Text] [Related]
48. Treatment-induced Treatment Sensitization in Metastatic Castration-resistant Prostate Cancer.
Gupta S; Heemers HV
Eur Urol; 2021 Jun; 79(6):734-735. PubMed ID: 33608156
[No Abstract] [Full Text] [Related]
49. Previously reported placebo-response-associated variants do not predict patient outcomes in inflammatory disease Phase III trial placebo arms.
Haug-Baltzell A; Bhangale TR; Chang D; Dressen A; Yaspan BL; Ortmann W; Brauer MJ; Hunkapiller J; Reeder J; Mukhyala K; Cuenco KT; Tom JA; Cowgill A; Vogel J; Forrest WF; Behrens TW; Graham RR; Wuster A
Genes Immun; 2019 Feb; 20(2):172-179. PubMed ID: 29550837
[TBL] [Abstract][Full Text] [Related]
50. Should we give metformin to all men with CRPC?
Clyne M
Nat Rev Urol; 2014 Feb; 11(2):63. PubMed ID: 24445914
[No Abstract] [Full Text] [Related]
51. Is Placebo Response Responsible for Many Phase III Failures?
Dumitrescu TP; McCune J; Schmith V
Clin Pharmacol Ther; 2019 Dec; 106(6):1151-1154. PubMed ID: 31713241
[No Abstract] [Full Text] [Related]
52. Immunoproteasome inhibition in CRPC.
Stone L
Nat Rev Urol; 2023 Mar; 20(3):130. PubMed ID: 36765186
[No Abstract] [Full Text] [Related]
53. Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.
Østergren PB; Murtola TJ; Fode M
Eur Urol; 2019 Jun; 75(6):938-939. PubMed ID: 30573315
[No Abstract] [Full Text] [Related]
54. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
[TBL] [Abstract][Full Text] [Related]
55. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.
Maroto P; Solsona E; Gallardo E; Mellado B; Morote J; Arranz JÁ; Gómez-Veiga F; Unda M; Climent MÁ; Alcaraz A
Crit Rev Oncol Hematol; 2016 Apr; 100():127-36. PubMed ID: 26363809
[TBL] [Abstract][Full Text] [Related]
56. Targeting molecular resistance in castration-resistant prostate cancer.
Chandrasekar T; Yang JC; Gao AC; Evans CP
BMC Med; 2015 Sep; 13():206. PubMed ID: 26329698
[TBL] [Abstract][Full Text] [Related]
57. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
[TBL] [Abstract][Full Text] [Related]
58. Emerging agents for the therapy of advanced prostate cancer.
Hathaway AR; Baker MK; Sonpavde G
Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
[TBL] [Abstract][Full Text] [Related]
59. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
60. New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer.
Assi R; Temraz S; Shamseddine A; Mukherji D
Curr Drug Targets; 2016; 17(3):290-302. PubMed ID: 26343110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
